BACKGROUND: Bacterial resistance among uropathogens is on the rise and has led to a decreased effectiveness of oral therapies. Fosfomycin tromethamine (fosfomycin) is indicated for uncomplicated urinary tract infections (UTIs) and displays in vitro activity against multidrug-resistant (MDR) isolates; however, clinical data assessing fosfomycin for the treatment of complicated or MDR UTIs are limited. METHODS: We conducted a retrospective evaluation of patients who received ≥1 dose of fosfomycin between January 2009 and September 2015 for treatment of a UTI. Patients were included if they had a positive urine culture and documented signs/symptoms of a UTI. RESULTS: Fifty-seven patients were included; 44 (77.2%) had complicated UTIs, 36 (63.2%) had MDR UTIs, and a total of 23 (40.4%) patients had a UTI that was both complicated and MDR. The majority of patients were female (66.7%) and elderly (median age, 79 years). Overall, the most common pathogens isolated were Escherichia coli (n = 28), Enterococcus spp. (n = 22), and Pseudomonas aeruginosa (n = 8). Twenty-eight patients (49.1%) were clinically evaluable; the preponderance achieved clinical success (96.4%). Fifteen out of 20 (75%) patients with repeat urine cultures had a microbiological cure. CONCLUSIONS: This retrospective study adds to the limited literature exploring alternative therapies for complicated and MDR UTIs with results providing additional evidence that fosfomycin may be an effective oral option.
BACKGROUND: Bacterial resistance among uropathogens is on the rise and has led to a decreased effectiveness of oral therapies. Fosfomycin tromethamine (fosfomycin) is indicated for uncomplicated urinary tract infections (UTIs) and displays in vitro activity against multidrug-resistant (MDR) isolates; however, clinical data assessing fosfomycin for the treatment of complicated or MDR UTIs are limited. METHODS: We conducted a retrospective evaluation of patients who received ≥1 dose of fosfomycin between January 2009 and September 2015 for treatment of a UTI. Patients were included if they had a positive urine culture and documented signs/symptoms of a UTI. RESULTS: Fifty-seven patients were included; 44 (77.2%) had complicated UTIs, 36 (63.2%) had MDR UTIs, and a total of 23 (40.4%) patients had a UTI that was both complicated and MDR. The majority of patients were female (66.7%) and elderly (median age, 79 years). Overall, the most common pathogens isolated were Escherichia coli (n = 28), Enterococcus spp. (n = 22), and Pseudomonas aeruginosa (n = 8). Twenty-eight patients (49.1%) were clinically evaluable; the preponderance achieved clinical success (96.4%). Fifteen out of 20 (75%) patients with repeat urine cultures had a microbiological cure. CONCLUSIONS: This retrospective study adds to the limited literature exploring alternative therapies for complicated and MDR UTIs with results providing additional evidence that fosfomycin may be an effective oral option.
Authors: Caroline G Elmer-Lyon; Judy A Streit; Elizabeth B Takacs; Patrick P Ten Eyck; Catherine S Bradley Journal: Int Urogynecol J Date: 2019-06-20 Impact factor: 2.894
Authors: María Ruiz-Ruigómez; Mario Fernández-Ruiz; José Tiago Silva; Elisa Vidal; Julia Origüen; Antonia Calvo-Cano; Enrique Luna-Huerta; Esperanza Merino; Domingo Hernández; Cristina Jironda-Gallegos; Rosa Escudero-Sánchez; Francesca Gioia; Antonio Moreno; Cristina Roca; Elisa Cordero; Darío Janeiro; Beatriz Sánchez-Sobrino; María Milagro Montero; Dolores Redondo; Francisco Javier Candel; Isabel Pérez-Flores; Carlos Armiñanzas; Claudia González-Rico; María Carmen Fariñas; Emilio Rodrigo; Belén Loeches; María O López-Oliva; Miguel Montejo; Ricardo Lauzurica; Juan Pablo Horcajada; Julio Pascual; Amado Andrés; José María Aguado; Francisco López-Medrano Journal: Antimicrob Agents Chemother Date: 2021-02-08 Impact factor: 5.191
Authors: Elizabeth C Smith; Hunter V Brigman; Jadyn C Anderson; Christopher L Emery; Tiffany E Bias; Phillip J Bergen; Cornelia B Landersdorfer; Elizabeth B Hirsch Journal: J Clin Microbiol Date: 2020-09-22 Impact factor: 5.948
Authors: Iain J Abbott; Elke van Gorp; Aart van der Meijden; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191